A Scoping Review on the Reported Evidence and Gaps of the Risk of Diabetes in Dyslipidemic Patients under Statin Therapy.
Level 5 - mechanism / opinion, no new human data
Scoping review synthesizing qualitative evidence without systematic risk-of-bias assessment or meta-analysis
PubMed 35892446 · doi:10.3390/clinpract12040060
What was done
A scoping review searched PubMed and Google Scholar to evaluate the risk of diabetes mellitus in dyslipidemic patients receiving statin therapy. From 822 identified records, 48 articles meeting inclusion and exclusion criteria were included in the synthesis.
What was found
The abstract reports no numerical effect sizes, relative risks, or statistical values. It reports qualitatively that statin users are potentially at higher risk of developing diabetes mellitus compared with non-users, and notes that the exact underlying mechanism remains unestablished.
Why it matters
It highlights the clinical concern of statin-associated diabetes risk across existing literature, emphasizing the need to identify underlying causes while managing dyslipidemia.
Limits
No quantitative synthesis, relative risk metrics, or confidence intervals are provided in the abstract. Scoping review methodology does not require formal risk-of-bias grading or quality appraisal of included studies. The search was restricted to two databases (PubMed and Google Scholar), and potential confounding factors such as statin type, dosage, duration, or baseline glycemic status are not reported.
Cited by
- supports Over 200 million people worldwide take statins on a daily basis.